Company intelligence / Profile preview

Mainline Biosciences

Malvern, Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Mainline Biosciences is developing novel peptide-based therapeutics and peptide-drug conjugates primarily targeting cancer and fibrotic diseases. Their lead assets are in preclinical development with a focus on the CXCR4 target for oncology and fibrosis indications. The company has described new PDCs targeting somatostatin receptors for cancer therapy.[3][7][10] No published late-stage clinical results as of May 2025.

Therapeutic areas: GastroenterologyOncologyPulmonologyNeurology
Modalities: Peptide drugsPeptide-drug conjugates (PDCs)Universal CAR-TSynthetic peptidesRecombinant polypeptides[6][7][10]
Industry: Biotech

Drug pipeline

7 assets

mb1707

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Mainline Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mainline Biosciences.

Explore the full profile